Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.59 |
| ▸ | AR | P10275 | 7/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Promegestone SCHEMBL27977093 | 0.97 | PGR (0.94) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL13918130 | 0.88 | PGR (0.79) | PGRNR3C1ARNR3C2CYP3A4 | |
| Demegestone SCHEMBL6851326 | 0.88 | PGR (0.78) | PGRNR3C1ARNR3C2CYP3A4 | |
| Demegestone SCHEMBL1649297 | 0.88 | PGR (0.78) | PGRNR3C1ARNR3C2CYP3A4 | |
| Demegestone SCHEMBL146550 | 0.88 | PGR (0.78) | PGRNR3C1ARNR3C2CYP3A4 | |
| Demegestone SCHEMBL28338894 | 0.86 | PGR (0.75) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL20959664 | 0.86 | PGR (0.75) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL19286040 | 0.85 | PGR (0.74) | PGRNR3C1ARNR3C2CYP3A4 | |
| Trimegestone SCHEMBL6847373 | 0.84 | PGR (0.72) | PGRNR3C1ARNR3C2CYP3A4 | |
| Trimegestone SCHEMBL13875056 | 0.84 | PGR (0.72) | PGRNR3C1ARNR3C2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2399 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | BAYER OY (FI) | 2026-02-26 | — | — | US | claimed |
| EP-4638443-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | claimed |
| US-20250255968-A1 | INTRAVAGINAL DEVICES FOR DRUG DELIVERY | KISER PATRICK F (US) | 2025-08-14 | — | — | US | claimed |
| US-12318395-B2 | Ethinyl estradiol-β-cyclodextrin complex and process for preparing thereof | LABORATORIOS LEON FARMA, S.A. (ES) | 2025-06-03 | — | — | US | claimed |
| WO-2024130344-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | claimed |
| EP-2040683-B2 | PHARMACEUTICAL COMPOSITION CONTAINING A TETRAHYDROFOLIC ACID | BAYER IP GMBH (DE) | 2023-08-16 | — | — | EP | claimed |
| EP-2116249-B2 | Pharmaceutical compound containing gestagens and/or oestrogens and 5-methyl-(6S)-tetrahydrofolates | BAYER IP GMBH (DE) | 2023-04-05 | — | — | EP | claimed |
| EP-4157242-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | Galera Labs, LLC (US) | 2023-04-05 | — | — | EP | claimed |
| US-20230071390-A1 | ASSESSMENT OF PR CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION | INNOSIGN B.V. (NL) | 2023-03-09 | — | — | US | claimed |
| EP-4126235-A2 | IDENTIFICATION AND USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | Vanda Pharmaceuticals Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | claimed |
| EP-0591432-A4 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION. | NOVEN PHARMA (US) | 1995-05-17 | — | — | EP | claimed |
| CN-1088778-A | Based on the drug delivery system of solubility parameters and the method for change medicine saturated concentration | NOVEN PHARMA (US) | 1994-07-06 | — | — | CN | claimed |
| EP-0591432-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1994-04-13 | — | — | EP | claimed |
| EP-0573576-A1 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS. | NOVEN PHARMA (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1993000058-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1993-01-07 | — | — | WO | claimed |
| WO-1992015289-A1 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1992-09-17 | — | — | WO | claimed |
| EP-0462189-A1 | COMBINATION THERAPY FOR TREATMENT OF ESTROGEN SENSITIVE DISEASES. | ENDORECHERCHE INC (CA) | 1991-12-27 | — | — | EP | claimed |
| WO-1990010462-A1 | COMBINATION THERAPY FOR TREATMENT OF ESTROGEN SENSITIVE DISEASES | ENDORECHERCHE INC. (CA) | 1990-09-20 | — | — | WO | claimed |
| EP-0003583-B1 | COMPOSITIONS FOR CYTOCHEMICAL INVESTIGATION, THEIR USE AND METHOD FOR THE DETECTION OF STEROID HORMONE RECEPTORS IN HUMAN TISSUES | Lee, Sin Hang (US) | 1981-12-02 | — | — | EP | claimed |